MKI67 and neoplasm: The immune microenvironment analysis revealed that Quetmolimab treatment significantly reduced the expression of exhaustion markers (Figure S5B,C, Supporting Information) and increased the tumor reactivity of CD8+ T cells (with elevated expression of Ki67, TNF, and IFN) (Figure S5D–F, Supporting Information), indicating a reduction in CD8+ T cell exhaustion.